Medically reviewed by Donald L. Gates, MD — Last reviewed June 2026

Tirzepatide for Medical Weight Loss in Coastal Georgia

Tirzepatide represents a significant development in obesity pharmacotherapy. Unlike earlier GLP-1 medications, tirzepatide is a dual agonist—it activates two separate hormone receptor pathways simultaneously, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism distinguishes it from semaglutide and other single-agonist GLP-1 medications and is associated with substantial weight reduction in clinical trials among eligible patients.

At Scale Solutions, Donald L. Gates, MD prescribes tirzepatide under its FDA-approved brand names—Mounjaro® and Zepbound®, both manufactured by Eli Lilly—for appropriately selected patients at our Savannah, Pooler, and Hinesville offices. We do not prescribe compounded tirzepatide. To schedule a consultation, call (912) 352-7546.

What Is Tirzepatide? Understanding the Dual Agonist Mechanism

To understand why tirzepatide works differently from other weight loss medications, it helps to understand the two hormone systems it targets.

GLP-1 (Glucagon-Like Peptide-1)

GLP-1 is a gut-derived hormone released after eating. It stimulates insulin secretion, suppresses glucagon (which lowers blood sugar), slows gastric emptying, and signals satiety in the brain. Semaglutide (Ozempic®, Wegovy®) is a single GLP-1 receptor agonist that acts on this pathway alone.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is another gut-derived incretin hormone with distinct receptor distribution and signaling effects. GIP receptors are found in adipose tissue, bone, and brain regions involved in energy homeostasis. Stimulating GIP receptors, in combination with GLP-1 receptor activation, appears to produce additive or synergistic effects on insulin secretion, fat cell metabolism, and appetite regulation. Exactly how the combined GIP/GLP-1 agonism produces greater weight loss than GLP-1 agonism alone is an area of ongoing research, but the clinical outcomes in tirzepatide trials suggest a meaningful incremental benefit.

The Dual Agonist Advantage

Tirzepatide is described as a “dual incretin receptor agonist” because it binds to and activates both the GIP receptor and the GLP-1 receptor. This is not simply the combination of two existing drugs—tirzepatide is a single purpose-designed molecule engineered to engage both receptor systems with a single weekly injection. The clinical trial data from Eli Lilly’s SURMOUNT program suggest that this dual mechanism produces weight loss outcomes that are generally greater than those seen with semaglutide in comparable patient populations, though individual results vary and no head-to-head comparison should be interpreted as a guarantee of personal outcomes.

FDA Approval Status

• Mounjaro® (tirzepatide 2.5 mg–15 mg): FDA-approved for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. Not FDA-approved as a primary weight management indication under this label.
• Zepbound® (tirzepatide 2.5 mg–15 mg): FDA-approved for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity, in conjunction with a reduced-calorie diet and increased physical activity. This is the appropriate FDA-approved weight management label for tirzepatide.

Scale Solutions prescribes tirzepatide within the framework of these FDA approvals. We do not prescribe compounded tirzepatide. Compounded tirzepatide preparations have not undergone FDA approval review, and the FDA has taken enforcement action against some compounders marketing unapproved tirzepatide products.

SURMOUNT Trials: What the Clinical Evidence Shows

Eli Lilly conducted the SURMOUNT clinical trial program to evaluate tirzepatide specifically for weight management in patients with and without type 2 diabetes. The SURMOUNT trials enrolled adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. In these trials:

• Participants treated with tirzepatide at the highest doses demonstrated substantial reductions in body weight over the course of the trial.
• The weight reductions observed were among the largest reported for any approved obesity pharmacotherapy to date.
• Results were measured alongside diet and exercise interventions, consistent with the FDA label, which specifies use “in conjunction with a reduced-calorie diet and increased physical activity.”

Important context for patients: Clinical trial results represent population averages under controlled conditions and include patients who reached maximum doses with good tolerability. Individual results vary. Not every patient reaches or tolerates the highest doses. Weight loss is a gradual process, and results depend on many factors including adherence, diet, activity, and individual metabolic response. Scale Solutions does not represent that any individual patient will achieve specific weight loss outcomes.

How Tirzepatide Differs from Semaglutide

Patients and referring physicians frequently ask how tirzepatide (Zepbound®) compares to semaglutide (Wegovy®). Here is a clinical summary:

• Mechanism: Tirzepatide activates both GIP and GLP-1 receptors (dual agonist); semaglutide activates GLP-1 receptors only (single agonist).
• Manufacturer: Tirzepatide is manufactured by Eli Lilly; semaglutide is manufactured by Novo Nordisk.
• Dosing range: Tirzepatide titrates from 2.5 mg to 15 mg weekly; semaglutide for weight management titrates from 0.25 mg to 2.4 mg weekly (different molecular weight, not directly comparable as a number).
• Side effect profiles: Both medications share a predominantly gastrointestinal side effect profile (nausea, constipation, vomiting, diarrhea). GI side effects with tirzepatide are broadly similar in character to those with semaglutide, with severity and frequency varying by individual and dose.
• Cost and insurance coverage: Both medications carry substantial list prices. Coverage by commercial insurance, Medicare, and Medicaid varies by plan. Cost and coverage may differ between the two products for a given patient.

The choice between tirzepatide and semaglutide is not simply “which one works better.” It involves clinical factors including your medical history, contraindications, insurance coverage, prior medication experience, and individual preference. Dr. Gates will discuss both options with you and help you identify which is the most appropriate starting point for your clinical situation. For a full overview of semaglutide, see our Semaglutide for Medical Weight Loss page.

Who Is a Candidate for Tirzepatide?

The FDA-approved indication for Zepbound® applies to adults with:

• BMI ≥ 30 kg/m², or
• BMI ≥ 27 kg/m² with at least one weight-related comorbidity

Tirzepatide shares several contraindications with other GLP-1 class medications, including:

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Severe GI disease, including gastroparesis
• Active or prior pancreatitis (relative contraindication, requires clinical judgment)
• Pregnancy or active breastfeeding

Patients on insulin or insulin secretagogues require careful monitoring for hypoglycemia when starting tirzepatide, as the medication has glucose-lowering effects. Dr. Gates will review your full medication list and history to identify any relevant interactions or contraindications before recommending tirzepatide.

Dosing Titration Schedule

Tirzepatide is initiated at a low dose and titrated upward over a minimum of 20 weeks to minimize GI side effects while building toward the therapeutic maintenance dose:

• Weeks 1–4: 2.5 mg once weekly (initiation dose; below therapeutic range for weight loss)
• Weeks 5–8: 5 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Weeks 13–16: 10 mg once weekly
• Weeks 17–20: 12.5 mg once weekly
• Week 21 and beyond: 15 mg once weekly (maximum dose)

Not every patient will reach or need to reach 15 mg. Some patients achieve adequate results at lower maintenance doses with better tolerability. Dr. Gates manages dose escalation individually and does not apply a forced maximum-dose protocol. If you experience persistent or significant side effects at a given dose, the titration schedule can be extended or paused until tolerability improves.

Tirzepatide is administered as a subcutaneous injection once weekly using a pre-filled pen device. Injection training is provided at your first treatment visit.

Side Effects: What to Expect

The side effect profile of tirzepatide is broadly consistent with GLP-1 class medications:

• Nausea: Most common, particularly following dose increases. Typically decreases as your body adapts.
• Constipation: A significant minority of patients experience constipation, which is manageable with hydration, fiber intake, and, if needed, stool softeners.
• Diarrhea: Less common than constipation but reported, particularly at higher doses.
• Vomiting: Occurs in some patients, especially if meals are too large or eaten too quickly.
• Decreased appetite: Expected and therapeutic, but can occasionally reduce caloric intake below adequate levels in some patients. Monitoring protein intake is important.
• Fatigue: Mild, transient fatigue reported by some patients.

Rare but serious adverse events include pancreatitis, gallbladder disease, and a warning regarding potential thyroid C-cell tumors (based on animal data; clinical relevance in humans is not established). Patients are counseled on signs and symptoms to report during the monitoring process.

Monitoring at Scale Solutions

Dr. Gates monitors all patients receiving tirzepatide through scheduled follow-up appointments. This includes weight and vital sign tracking, side effect assessment, dietary review, and lab monitoring as clinically appropriate. Dose decisions are made by Dr. Gates at each visit based on your progress and tolerability—not by an automated protocol. Patients with concerns between appointments can contact the office directly.

Cost and Insurance for Tirzepatide

Zepbound® list prices are substantial. Coverage by commercial insurance plans varies; some plans cover tirzepatide for obesity, while others exclude it. Eli Lilly has savings programs that may reduce out-of-pocket cost for eligible commercially insured patients. Medicare coverage for obesity pharmacotherapy is limited but evolving. Scale Solutions staff can assist you in understanding your options at intake.

For full program pricing, visit our Pricing page. If tirzepatide coverage is a concern, Dr. Gates can discuss whether semaglutide (see our Semaglutide page) may be covered under your plan at a lower out-of-pocket cost.

Frequently Asked Questions — Tirzepatide